Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 28:14:1248985.
doi: 10.3389/fendo.2023.1248985. eCollection 2023.

Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours

Valentina Guarnotta  1 , Fabrizio Emanuele  1 , Riccardo Salzillo  1 , Maria Bonsangue  1 , Carlotta Amato  1 , Mariagrazia Irene Mineo  1 , Carla Giordano  1
Affiliations
Review

Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours

Valentina Guarnotta et al. Front Endocrinol (Lausanne). .

Abstract

Cushing's syndrome, acromegaly and neuroendocrine disorders are characterized by an excess of counterregulatory hormones, able to induce insulin resistance and glucose metabolism disorders at variable degrees and requiring immediate treatment, until patients are ready to undergo surgery. This review focuses on the management of diabetes mellitus in endocrine disorders related to an excess of counterregulatory hormones. Currently, the landscape of approved agents for treatment of diabetes is dynamic and is mainly patient-centred and not glycaemia-centred. In addition, personalized medicine is more and more required to provide a precise approach to the patient's disease. For this reason, we aimed to define a practical therapeutic algorithm for management of diabetes mellitus in patients with glucagonoma, pheochromocytoma, Cushing's syndrome and acromegaly, based on our practical experience and on the physiopathology of the specific endocrine disease taken into account. This document is addressed to all specialists who approach patients with diabetes mellitus secondary to endocrine disorders characterized by an excess of counterregulatory hormones, in order to take better care of these patients. Care and control of diabetes mellitus should be one of the primary goals in patients with an excess of counterregulatory hormones requiring immediate and aggressive treatment.

Keywords: GH secreting; catecholamine; cortisol; counterregulatory hormones; glucagonoma; pheochromocytoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Therapeutic algorithm of diabetes mellitus secondary to glucagonoma and pheochromocytoma. A1c, glycated haemoglobin; CVD, cardiovascular disease; DPP4-i, Dipeptidyl peptidase inhibitors.
Figure 2
Figure 2
Therapeutic algorithm of diabetes mellitus secondary to Cushing’s syndrome. A1c, glycated haemoglobin; DPP4-i, Dipeptidyl peptidase inhibitors; SGLT2-i, sodio-glucose co-transporters 2 inhibitors.
Figure 3
Figure 3
Therapeutic algorithm of pasireotide-related hyperglycaemia in patients with Cushing’s syndrome and acromegaly. CVD, cardiovascular disease; A1c, glycated haemoglobin; SGLT2-i, sodio-glucose co-transporters 2 inhibitors.
Figure 4
Figure 4
Therapeutic algorithm of diabetes mellitus secondary to acromegaly. A1c, glycated haemoglobin; CVD, cardiovascular disease; SGLT2-i, sodio-glucose co-transporters 2 inhibitors; DPP4-i, Dipeptidyl peptidase inhibitors.
See this image and copyright information in PMC

References

    1. Ferraù F, Albani A, Ciresi A, Giordano C, Cannavò S. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol (2018) 9:358. doi: 10.3389/fendo.2018.00358 - DOI - PMC - PubMed
    1. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. . 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care (2023) 46(Supplement_1):S140–57. doi: 10.2337/dc22-S009 - DOI - PMC - PubMed
    1. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. (2017) 60(9):1577–85. doi: 10.1007/s00125-017-4342-z - DOI - PMC - PubMed
    1. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol (2012) 13(4):251–62. doi: 10.1038/nrm3311 - DOI - PMC - PubMed
    1. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. (2017) 60(9):1586–93. doi: 10.1007/s00125-017-4336-x - DOI - PubMed

MeSH terms